Neuromodulation News and Research

RSS

Alim Louis Benabid, Mahlon DeLong jointly win 2014 Lasker-DeBakey Clinical Medical Research Award

French neurosurgeon Alim Louis Benabid and American neurologist Mahlon DeLong were recently named winners of the 2014 Lasker-DeBakey Clinical Medical Research Award for their roles in developing deep brain stimulation (DBS) for the treatment of Parkinson disease.

2 Dec 2014

electroCore CEO highlights the importance of working with stakeholders when launching new technologies

JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers within the payor community at the earliest opportunity, particularly in regards to innovative and disruptive technology such as electroCore’s non-invasive vagus nerve stimulation (nVNS).

26 Nov 2014

Cyberonics' worldwide net sales increase 5% to $73.4M in Q2 of fiscal 2015

Cyberonics, Inc. today announced results for the quarter ended October 24, 2014.

20 Nov 2014

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

The pros and cons of medical marijuana is a discussion focus at the fifth annual Queensland Epilepsy Symposium, Epilepsy – On the Horizon.

18 Nov 2014

NeuroSigma, VA partner to evaluate eTNS system for TBI patients in Phase I clinical trial

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs for a clinical trial to evaluate the benefits of non-invasive, external Trigeminal Nerve Stimulation (eTNS) for patients with traumatic brain injury (TBI) in a Phase I clinical trial.

15 Oct 2014

USC researchers develop new methods to advance study of human brains, epilepsy

USC biomedical engineers, neurologists and neurosurgeons develop new methods to advance the study of human brains and epilepsy. Studying the human brain is logistically complicated. Living samples of the complex and sensitive organ are limited and difficult to preserve, which means that research on them must be conducted quickly before they expire.

8 Oct 2014

Neuromod Devices receives ISO 13485 certification of Quality Management System

Neuromod Devices, the Irish medical devices company, today announced that it has successfully secured ISO 13485 certification of its Quality Management System.

19 Sep 2014

Sacral neuromodulation augments efficacy of antimuscarinics in OAB

The addition of sacral neuromodulation to antimuscarinic pharmacotherapy offers significant benefits over antimuscarinics alone in the treatment of women with idiopathic overactive bladder, study findings show.

17 Sep 2014

Vercise DBS System receives CE Mark approval for treatment of essential tremor

Boston Scientific Corporation has received CE Mark for the Vercise Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement disorder known as essential tremor (ET).

17 Sep 2014

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

Chronic pain, which persists despite the fact that an injury has healed, can last for many months or years and may affect up to 15 percent of the adult population at any point in time.

13 Aug 2014

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Reflecting groundbreaking international consensus regarding a group of rapidly evolving medical interventions for chronic pain, the International Neuromodulation Society announced it will soon publish the first peer-reviewed comprehensive expert guidance on the appropriate use of neurostimulation for pain.

12 Aug 2014

NGS issues positive coverage decision for PTNS to manage symptoms of OAB

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that National Government Services has issued a positive coverage decision for Posterior Tibial Nerve Stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence associated with overactive bladder (OAB). Coverage for the proprietary Urgent PC device was effective August 10, 2014.

12 Aug 2014

NIH funds Phase II 90-subject pediatric clinical trial at UCLA

NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System.

10 Jul 2014

UCLA project receives $15M to restore lost memory functions in brain-injured people

The UCLA Program in Memory Restoration has been awarded up to $15 million by the Defense Advanced Research Projects Agency (DARPA) for a four -year project aiming to help brain-injured people restore lost memory functions.

9 Jul 2014

Sacral nerve stimulation for patients with birth defect

Heather Rayser, 16, has a colon that does not function properly and as a result, she has never been to high school and has been on home hospital care for nine years.

17 Jun 2014

Uroplasty participates in 9th Annual JMP Securities Healthcare Conference

Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 9th Annual JMP Securities Healthcare Conference on Tuesday, June 24.

16 Jun 2014

St. Jude Medical's EnligHTN renal denervation system safe, effective for treating drug-resistant hypertension

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced preliminary results from the EnligHTN III study, which found the company's second-generation EnligHTN™ renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure. The results were presented during a hot line late-breaking clinical trial session at EuroPCR 2014.

22 May 2014

Anti-depressants could slow onset of Alzheimer's disease

A University of Pennsylvania researcher has discovered that the common selective serotonin reuptake inhibitor (SSRI) citalopram arrested the growth of amyloid beta, a peptide in the brain that clusters in plaques that are thought to trigger the development of Alzheimer's disease (AD).

15 May 2014

St. Jude Medical presents new data on quadripolar technology at Heart Rhythm 2014

St. Jude Medical, Inc., a global medical device company, is the leader in quadripolar technology with the only cardiac resynchronization therapy (CRT) system approved in the U.S. New data presented at Heart Rhythm 2014, the Heart Rhythm Society's Annual Scientific Sessions, demonstrates increased survival, improved clinical outcomes and better cost utilization with St. Jude Medical's quadripolar technology.

9 May 2014

St. Jude Medical's net sales increase 2% in first quarter 2014

St. Jude Medical, Inc. today reported sales and net earnings for the first quarter ended March 29, 2014.

16 Apr 2014